Prostate Cancer
Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial.
January 29, 2024
The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
January 29, 2024
Interactive training workshop to improve prostate mpMRI knowledge: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship.
January 26, 2024
Functional Outcomes After Localized Prostate Cancer Treatment.
January 26, 2024
Impact of PSMA PET on Prostate Cancer Management.
January 26, 2024
Deep Learning-Based Detection and Classification of Bone Lesions on Staging Computed Tomography in Prostate Cancer: A Development Study.
January 25, 2024
Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making.
January 25, 2024
Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study.
January 25, 2024
Physician Perception of Grade Group 1 Prostate Cancer.
January 25, 2024
First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients.
January 24, 2024
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
January 24, 2024